Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Imatinib Mesylate 23Cyclophosphamide 18fludarabine 17fludarabine phosphate 13Busulfan 12Whole-Body Irradiation 11nilotinib 10Dasatinib 9thymoglobulin 8ponatinib 8Mycophenolic Acid 8Cytarabine 7Antilymphocyte Serum 7peginterferon alfa-2b 6Tacrolimus 6Cyclosporine 6Clofarabine 6Thiotepa 5Stem Cell Transplantation 4Sirolimus 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Alemtuzumab 4sargramostim 3Interferon-alpha 3Homoharringtonine 3Cord Blood Stem Cell Transplantation 3Bortezomib 3zileuton 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × milatuzumab × Clear all
NCT01663766 2021-08-19

Phase I Study of Milatuzumab for Graft Versus Host Disease

Gilead Sciences

Phase 1 Terminated
12 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡